Search. Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registered. 0000097745FALSE00000977452020-12-012020-12-010000097745us-gaap:CommonStockMember2020-12-012020-12-010000097745tmo:SeniorNotes2.15Due2022Member2020-12-012020-12-010000097745tmo:SeniorNotes0.75Due2024Member2020-12-012020-12-010000097745tmo:SeniorNotes0.125Due2025Member2020-12-012020-12-010000097745tmo:SeniorNotes200Due2025Member2020-12-012020-12-010000097745tmo:SeniorNotes1.40Due2026Member2020-12-012020-12-010000097745tmo:A1.45SeniorNotesDue2027Member2020-12-012020-12-010000097745tmo:SeniorNotes175Due2027Member2020-12-012020-12-010000097745tmo:SeniorNotes0.500Due2028Member2020-12-012020-12-010000097745tmo:SeniorNotes1.375Due2028Member2020-12-012020-12-010000097745tmo:SeniorNotes1.95Due2029Member2020-12-012020-12-010000097745tmo:SeniorNotes0.875Due2031Member2020-12-012020-12-010000097745tmo:SeniorNotes2375Due2032Member2020-12-012020-12-010000097745tmo:SeniorNotes2.875Due2037Member2020-12-012020-12-010000097745tmo:SeniorNotes1.500Due2039Member2020-12-012020-12-010000097745tmo:SeniorNotes1.875Due2049Member2020-12-012020-12-01, UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Date of Report (Date of earliest event reported): December 1, 2020, (Exact name of Registrant as specified in its Charter), (Address of principal executive offices) (Zip Code), Registrant’s telephone number, including area code: (781) 622-1000, Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (, Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425), Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12), Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)), Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Add to calendar ›, Legal Notice: Once approved; Testing with the Thermo Fisher Scientific Amplitude Solution described in this presentation will be designed and intended (i) for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures (ii)  for use under the Food and Drug Administration’s Emergency Use Authorization. Introducing the upcoming Thermo Fisher Scientific Amplitude Solution—a highly-automated molecular diagnostic testing system that can analyze over 6,000 specimens in a single day with the reliability and confidence of assured assay and reagent supply, along with 24/7 world class service and support. Applied Biosystems TaqPath COVID-19 Combo Kit: For Emergency Use Authorization (EUA) only. Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. • Linda Hasadsri, MD, PhD, Director of Genomics Laboratory, Mayo Clinic • Jose Luis Costa, PhD, Director of Medical Affairs, Thermo Fisher Scientific, A next-generation DNA sequencing assay for detection of SNV, insertion, deletion, and copy number variants in 25 Lymphoma genes in FFPE samples Poster # H12, Tuesday, November 17, 1:00 – 2:00 pm EST Presenter: Steve Roman Add to calendar ›, Characterization of the immunoglobulin heavy- and light-chain repertoires in a single reaction Poster # H17, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Geoffrey Lowman Add to calendar ›, Improved clonality and somatic hypermutation analysis of CLL with a highly multiplex IGHV assay Poster # H19, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Michelle Toro Add to calendar ›, Developing multiplex of real-time PCR assays for simultaneous detection and differentiation of COVID-19 plus Flu A and Flu B in a single tube format Poster # ID18, Tuesday, November 17, 1:00 – 2:00 pm EST Presenter: Chunling Wang Add to calendar ›, Characterization and evaluation of Acrometrix HIV, HBV, and HCV whole process quality controls for molecular diagnostic tests using Cobas® 6800 system Poster # ID61, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Hui Wang Add to calendar ›, Investigating targeted next-generation sequencing of 16s rRNA as a tool for detecting Shiga toxin-producing E.coli and salmonella in ground beef Poster # ID55, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Janice Au-Young Add to calendar ›, Highly scalable and automated approach to gut microbiome profiling and quantification using a new Ion Torrent next-generation sequencing assay Poster # I07, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Shruti Sarda Add to calendar ›, Prediction of DDR and other mutation signatures using panel-based sequencing Poster # I09, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Fiona Hyland Add to calendar ›, A comprehensive approach for detection of known and novel gene fusions with RNA sequencing Poster # ST19, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Amir Marcovitz Add to calendar ›, Internal validation and performance characteristics using the Oncomine™ Precision Assay to detect multiple variant types from solid and liquid biopsy samples Poster # ST31, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Jeff Schageman Add to calendar ›, Utilization of a targeted next-generation sequencing assay for assessment of tumor cellularity, and genome-wide and gene-specific loss of heterozygosity (LOH) Poster # ST29, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Mohit Gupta Add to calendar ›, Pushing the limits of cancer research: An integrated and automatic workflow on Ion Torrent Genexus System from nucleic acid extraction to next-generation sequencing Poster # TT20, Tuesday, November 17, 1:00 – 2:00 pm EST Presenter: Ru Cao Add to calendar ›, Next day analysis from specimen to variant calling with the Ion Torrent Genexus System Poster # TT19, Thursday, November 19, 1:00 – 2:00 pm EST Presenter: Jason Gioia Add to calendar ›. These returns cover a period from January 1, 1988 through October 5, 2020. Thermo Fisher Scientific will hold its earnings conference call today, July 22, 2020, at 8:30 a.m. Eastern time. For prescription use only. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. Our Mission is to enable our customers to make the world healthier, cleaner and … Add to calendar ›. • Peter Silvester,  Senior Vice President, Thermo Fisher Scientific • Paul Granato, PhD, Director of Microbiology, Laboratory Alliance of Central New York, Join our speakers in a live Q&A session Monday, November 16 at 1pm PST/4pm EST. For Research Use Only. Item 7.01 Regulation FD Disclosure. The Association for Molecular Pathology (AMP) Annual Meeting and Expo is the leading event for molecular pathologists, medical professionals, lab directors, and translational scientists to explore technical advancements that lead to better patient care. Speakers will also present recent data and discuss how these solutions address current challenges in their oncology research. At Fisher College, we believe that college is more than just an education—it's a life-changing experience. During this workshop, speakers will review the rapidly evolving biomarker landscape and latest clinical research data in NSCLC, with focus on several emerging new biomarkers, such as EGFR Exon 20 insertions. Marc N. Casper — Chairman, … of $19.17, which would represent 55% adjusted EPS growth over 2019, compared to the original expected year-over-year adjusted EPS growth of 48% that the Company provided on October 21, 2020. • Yi Ding, MD, PhD, System and Core Lab Director of Molecular Diagnostics, Geisinger Medical Laboratories • Jon Sherlock, PhD, Director of Product Management, Thermo Fisher Scientific, Join our speakers in a live Q&A session Wednesday, November 18 at 12:30pm PST/3:30pm EST. WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and … • Kelli Bramlett, PhD, Director of Research and Development, Thermo Fisher Scientific. Researchers are now adopting NGS to interrogate the SARS-CoV-2 genome across multiple samples simultaneously for contact tracing and to rapidly obtain a global picture for surveillance. Thermo Fisher Scientific offers chemicals, reagents, and materials to enable innovation, increase productivity and improve safety. Tracking the global spread and evolution of SARS-CoV-2 is important for epidemiology research, which is essential to help adapt and establish possible preventative measures and potential treatment options. Thermo Fisher Scientific Elects New Director to Board PR Newswire WALTHAM, Mass., Nov. 20, 2020 WALTHAM, Mass., Nov. 20, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: … Thermo Fisher Scientific Training. Press Release Biobanking Market May Set New Growth Story in Next 5 Years: Beckman Coulter, Thermo Fisher, Panasonic Published: Nov. 23, 2020 at 8:16 p.m. Thermo Fisher Scientific Inc. Q2 2020 earnings call dated Jul. In this webinar, we will cover effective strategies for establishing such testing channels, the operational requirements, and testing solutions that are up to the challenge. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. The timing and amount of these items are uncertain and could be material to Thermo Fisher’s results computed in accordance with GAAP. Jump to: Corporate workshops | Scientific posters | Virtual booth. THERMO FISHER SCIENTIFIC company earnings calendar and analyst expectations - Upcoming and past events | Nyse: TMO | Nyse. Search All . Search Thermo Fisher Scientific. For prescription use only. This year, AMP is hosting a virtual education and networking experience, and we are proud to continue our sponsorship. However, with the advent of new technologies comes an equally important need for novel reference materials and quality assessment schemes to ensure quality test implementation. As a non-profit organization, we count on the support of our partners and sponsors to help us continue to provide this … In recent years, next-generation sequencing (NGS) has emerged as a powerful tool for complex mutational profiling, owing to its ability to rapidly and simultaneously interrogate multiple genomic alterations from a single sample. From the initial launch in January to Emergency Use Authorization and global approvals in March to subsequent developments to enable more laboratories to do more testing, our kit has become a central component of many COVID-19 protocols around the world. Liquid biopsy is a non-invasive method for identifying biomarkers present in circulating tumor DNA (ctDNA). … • Emily Zeringer, Staff Scientist, Thermo Fisher Scientific. Among other topics, Mr. Casper will provide the Company’s current perspective on the impact of the COVID-19 pandemic. Actual results could be different from these estimates given the greater-than-normal uncertainty that continues to exist in the marketplace. As you plan your AMP itinerary, be sure to stop by our virtual booth. 2020 Upcoming Shows Event schedule is … To listen, dial (877) 273-7122 within the U.S. or (647) 689-5496 outside the U.S. Create Account, http://www.thermofisher.com/us/en/home/about-us/events/clinical/amp2020.html, Applied Biosystems TaqPath COVID-19 Combo Kit: For Emergency Use Authorization (EUA) only. For in vitro diagnostic use. Nov 30, 2020 11:30AM EST I nvestors focused on the Medical space have likely heard of Thermo Fisher Scientific (TMO), but is the stock performing well in comparison to the rest of its sector … • Mark Stevenson, Executive Vice President and Chief Operating Officer, Thermo Fisher Scientific • Robert Balog, Director, Engineering Systems Design, Thermo Fisher Scientific • Elliot Shelton, Senior Director, High Throughput Program Manaement, Thermo Fisher Scientific, Join our speakers in a live Q&A session Wednesday, November 18 at 1:30pm PST/4:30pm EST. In this workshop, some of those laboratories will share clinical data and discuss how our solutions are helping in the fight against SARS-CoV-2. Not for use in diagnostic procedures. Thermo Fisher Scientific. We invite you to join us virtually as we showcase an unprecedented nine corporate workshops covering innovations for SARS-CoV-2, liquid biopsy testing, carrier screening, and myeloid and comprehensive genomic profiling. You can access new videos, the latest literature, and our team. Vice President and Chief Accounting Officer. The better-than-expected organic revenue growth is driven by increased levels of organic growth in both the base business and COVID-19 response revenue. For more than a century, Fisher has been changing lives by providing opportunities to students … Thermo Fisher Scientific is a Partner Sponsor of the 2020 iGEM Competition. The following slide deck was published by Thermo Fisher Scientific Inc. in conjunction with their 2020 Q2 earnings call.. Nov 19, 2020 8:14AM EST As of late, it has definitely been a great time to be an investor in Thermo Fisher Scientific Inc. TMO . Our second speaker, Jose Luis Costa, PhD, is a Director of Medical Affairs at Thermo Fisher Scientific. You will have opportunities to engage with our team during our corporate workshops, scientific poster presentations, and virtual booth. The medical research company reported $5.63 EPS for the quarter, topping analysts' consensus estimates of $4.37 by $1.26. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Current Report on Form 8-K. Testing is limited to laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. Nov 16, 2020 - Nov 20, 2020 Virtual experience The Association for Molecular Pathology (AMP) Annual Meeting and Expo is the leading event for molecular pathologists, medical professionals, lab directors, and translational scientists to explore technical advancements that lead to better patient care. DNA Day April 25, 2020 AACR Annual Meeting 2020 April 24–29, 2020 … Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company’s most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available in the “Investors” section of its Website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Don't have an account ? Laboratories are being told that COVID-19 testing volumes must increase to help restore our communities back to some degree of normality. DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher … • Amy Carroll PhD, Director of Medical Affairs, Thermo Fisher Scientific • Timothy Triche, MD, PhD, Co-Director, Center for Personalized Medicine Program, Children's Hospital of Los Angeles • Nicky D'Haene, MD, PhD, Professor in Pathology, Hospital Erasme. Marc N. Casper — Chairman, … The oncologist and pathologist speakers will highlight how the paradigm change in NSCLC impacts their practice, and the importance of NGS and fast TAT results to enable best treatment decision. Home › Promotions › EPM Tradeshow Calendar. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. Environmental and Process Monitoring Event Calendar. ... Q3 2020 Präsentation des Ergebnisses: 10/21/20 | 12:00pm : Q3 2020 … Add to calendar As previously announced, Marc N. Casper, Chairman, President and Chief Executive Officer of Thermo Fisher Scientific Inc. (the “Company”), will be participating today in a virtual fireside chat at the Evercore ISI HealthCONx Conference. Thermo Fisher Scientific Inc Q3 2020 earnings call dated Oct. 21, 2020Corporate Participants: Kenneth J. Apicerno — Vice President, Investor Relations. Thermo Fisher Scientific last posted its earnings data on October 21st, 2020. The information contained in Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Thermo Fisher Scientific workflows around viral nucleic acid extraction and detection, including our newly developed method for use with saliva which has become an appealing alternative to common swab techniques and an increasingly popular sample type for viral nucleic acid detection. Additionally, Mr. Casper will communicate expected full year 2020 adjusted earnings per share (“EPS”). To listen, dial (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S. ET Dr. Costa will present the analytic verification of a novel NGS assay for expanded carrier screening research. THERMO FISHER SCIENTIFIC company earnings calendar and analyst expectations - Upcoming and past events | Nyse: TMO | Nyse. ... Calendar. Cautionary Statement Regarding Forward-Looking Statements. For, Spectroscopy, Elemental & Isotope Analysis, Preclinical to Companion Diagnostic Development, Chromatography Columns, Resins, & Spin Filters. Search Thermo Fisher Scientific ... Thermo Fisher Scientific is performing better than its sector in the calendar year. Thermo Fisher Scientific has launched its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell … This update will include expected fourth quarter organic revenue. As previously announced, Marc N. Casper, Chairman, President and Chief Executive Officer of Thermo Fisher Scientific Inc. (the "Company"), will be … Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. Thermo Fisher excludes the above items because they are outside of the company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Rare Disease Day™ 2020 February 29, 2020 APRIL World Health Day April 7, 2020 Earth Day™— 50th Anniversary April 22, 2020 Life in the Lab will be going GREEN— stay tuned online. Join this workshop to hear Linda Hasadsri, MD, PhD, Co-Director of the Genomics Laboratory at Mayo Clinic, share an educational overview of expanded carrier screening (ECS). Thermo Fisher Scientific will hold its earnings conference call today, October 21, 2020, at 8:30 a.m. Eastern time. Adjusted earnings per share is a non-GAAP measure that excludes certain items detailed later in this Form 8-K under the heading "Use of Non-GAAP Financial Measures.". In this workshop, speakers will present their experience with rapid and highly automated targeted NGS workflows for analyzing SARS-CoV-2, enabling labs to go from sample to report in a single day with minimal hands-on time. or predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. Start date End date Start time End time Price Language … As liquid biopsy technologies become more sensitive, screening for early cancer detection using a blood test could become routine clinical practice. This Current Report on Form 8-K contains forward-looking statements that involve a number of risks and uncertainties, including statements about fourth quarter revenue and impacts of the COVID-19 pandemic. ... Strong Buy Stocks to Close Out 2020. Thermo Fisher believes that the use of non-GAAP measures helps investors to gain a better understanding of the company's core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. CBD: Carlsbad, CA : FRD: Frederick, MD : REG: Regional : WEB: Web-Based Training: November 2020. • Jyoti D. Patel, MD, FASCO, Associate Vice Chair for Clinical Research, Professor of Medicine, Northwestern Medicine • Amir Behdad, MD, MBA, Associate Professor of Hematopathology, Medicine and Molecular Pathology, Northwestern Medicine, Co-sponsored with Takeda Pharmaceuticals. • Jared Auclair, PhD, Associate Dean of Professional Programs, College of Science, Northeastern University • Frank Ong, MD, Chief Medical and Scientific Officer, Everlywell. Press Release Thermo Fisher Scientific Elects New Director to Board Published: Nov. 20, 2020 at 4:05 p.m. growth of 40%, compared to the original expected fourth quarter organic revenue growth of 29% that the Company provided on October 21, 2020, when it announced its third quarter 2020 results, which would translate to full year 2020 organic revenue growth of approximately 22%. 22, 2020Corporate Participants: Kenneth Apicerno — Vice President, Investor Relations. ... Calendar. Thermo Fisher excludes the above items because they are outside of the company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. As the world continues to contend with the SARS-CoV-2 outbreak, Thermo Fisher Scientific continues to arm laboratories with the widest, most innovative selection of COVID-19 testing solutions that meet the needs of the communities in which they operate. Organic revenue is reported revenue excluding the impact of acquisitions and divestitures and foreign currency translation. This workshop focuses on solutions that equip laboratories to participate in expanding testing and screening regimes for students, office employees, athletes, tourists, and more. Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Add to calendar › Access workshop ›. Testing volumes need to increase by orders of magnitude in order to restore communities back to normality. Additionally, Dr. Hasadsri will share the ECS experience at Mayo, including a deep dive into several interesting case studies illustrating the complexities of ECS. Start date End date Start time End time Price Location; MB … Recent ctDNA detection technologies could potentially revolutionize early cancer detection. Whether you are looking for a new solution, or need some answers to a question, our experts are standing by and ready to help. We are unable to reconcile organic revenue to reported revenue because the timing and amount of these items are uncertain and could be material to Thermo Fisher’s reported results. During this workshop, speakers will discuss their perspective and experience with new automated solutions for Oncomine Myeloid Assay GX, a revolutionary approach to myeloid profiling that enables specimen-to-report automation in a single day, and Oncomine Comprehensive Assay Plus, an end-to-end solution that distills hundreds of genes into a report in as little as three days. With a portfolio of over 100,000 products, we offer choice and supply … WALTHAM, Mass., Nov. 20, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected R. Alexandra "Alex" Keith to its ET In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), Thermo Fisher uses certain non-GAAP financial measures, including adjusted EPS, which excludes certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; amortization of acquisition-related intangible assets; certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity. ... Thermo Fisher Scientific. Attend this workshop to see the performance data and hear from early-access customers. But how can laboratories scale while minimizing costs, and with the confidence of assurance of uninterrupted supply of tests and reagents? Thermo Fisher Scientific Training. § 263a, to perform high complexity tests.​. City/Country: Regional: City/Country: Tours & Workshops: WEB: Web-Based Training: December 2020. They will share their best practices working together as a care team, the values of tumor boards and implementing NGS in-house.
2020 thermo fisher calendar 2020